TY - JOUR
T1 - Heparanase
T2 - a potential marker of worse prognosis in estrogen receptor-positive breast cancer
AU - Zahavi, Tamar
AU - Salmon-Divon, Mali
AU - Salgado, Roberto
AU - Elkin, Michael
AU - Hermano, Esther
AU - Rubinstein, Ariel M.
AU - Francis, Prudence A.
AU - Di Leo, Angelo
AU - Viale, Giuseppe
AU - de Azambuja, Evandro
AU - Ameye, Lieveke
AU - Sotiriou, Christos
AU - Salmon, Asher
AU - Kravchenko-Balasha, Nataly
AU - Sonnenblick, Amir
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/5/28
Y1 - 2021/5/28
N2 - Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10−10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospective randomized trial which showed that heparanase protein expression is associated with increased risk of recurrence in ER+ breast tumors (log-rank p = 0.004). In vitro experiments showed that heparanase promoted tumor progression and increased cell viability via epithelial–mesenchymal transition, stemness, and anti-apoptosis pathways in luminal breast cancer. Taken together, our results demonstrated that heparanase is associated with worse outcomes and increased cell viability in ER+ BC.
AB - Heparanase promotes tumor growth in breast tumors. We now evaluated heparanase protein and gene-expression status and investigated its impact on disease-free survival in order to gain better insight into the role of heparanase in ER-positive (ER+) breast cancer prognosis and to clarify its role in cell survival following chemotherapy. Using pooled analysis of gene-expression data, we found that heparanase was associated with a worse prognosis in estrogen receptor-positive (ER+) tumors (log-rank p < 10−10) and predictive to chemotherapy resistance (interaction p = 0.0001) but not hormonal therapy (Interaction p = 0.62). These results were confirmed by analysis of data from a phase III, prospective randomized trial which showed that heparanase protein expression is associated with increased risk of recurrence in ER+ breast tumors (log-rank p = 0.004). In vitro experiments showed that heparanase promoted tumor progression and increased cell viability via epithelial–mesenchymal transition, stemness, and anti-apoptosis pathways in luminal breast cancer. Taken together, our results demonstrated that heparanase is associated with worse outcomes and increased cell viability in ER+ BC.
UR - https://www.scopus.com/pages/publications/85106994943
U2 - 10.1038/s41523-021-00277-x
DO - 10.1038/s41523-021-00277-x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34050190
AN - SCOPUS:85106994943
SN - 2374-4677
VL - 7
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 67
ER -
